secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001104659-26-018128
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec real-world data show PEDMARK safe in adults with head & neck cancers, no disruption to cisplatin therapy
--------------------------------------------------------------------------------

- Data from retrospective review of 15 adult HNC patients presented at 2026 MHNCS symposium (Feb 19-21).
- PEDMARK given ≥6 hours after cisplatin was feasible and well tolerated; no grade 3/4 toxicities observed.
- Majority of high-risk patients had no measurable hearing loss during or after treatment despite baseline impairment.
- No disruption to curative-intent cisplatin-based treatment delivery was noted in the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926018128/0001104659-26-018128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926018128/fencf-20260220x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer